Reuters logo
BRIEF-BioLife solutions executes 10 year supply agreement with TissueGene for CryoStor use in Invossa osteoarthritis cell-mediated gene therapy
December 20, 2016 / 11:14 AM / a year ago

BRIEF-BioLife solutions executes 10 year supply agreement with TissueGene for CryoStor use in Invossa osteoarthritis cell-mediated gene therapy

Dec 20 (Reuters) - BioLife Solutions Inc

* BioLife Solutions-For U.S. market, TissueGene has received special protocol assessment designation for phase 3 trials scheduled to begin in Q2 of 2017

* BioLife Solutions-Mitsubishi Tanabe will proceed with Japanese clinical trials, filings; Kolon Life will be responsible for manufacturing activities

* BioLife Solutions executes 10 year supply agreement with TissueGene for CryoStor use in Invossa osteoarthritis cell-mediated gene therapy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below